Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Sponsor: Rapport Therapeutics Inc.
Summary
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
333
Start Date
2026-06-05
Completion Date
2029-09
Last Updated
2026-06-16
Healthy Volunteers
No
Conditions
Interventions
RAP-219
RAP-219 high dose tablets administered orally daily
RAP-219
RAP-219 medium dose tablets administered orally daily
Placebo
Matching placebo tablets administered orally daily
Locations (3)
Amicis Research Center
Palmdale, California, United States
Indiana University Health Fort Wayne Neurology
Fort Wayne, Indiana, United States
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland, United States